Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032187 | 0.81 | ARG1 (0.34) | — | |
| SCHEMBL250459 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL163395 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL122347 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL159315 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL173401 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL201078 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| SCHEMBL28833359 | 0.75 | ALDH1A1 (0.50) | DPP4ALDH1A1KDM4E | |
| Methane SCHEMBL8655712 | 0.74 | ALDH1A1 (0.48) | DPP4ALDH1A1KDM4E | |
| SCHEMBL22029349 | 0.74 | ALDH1A1 (0.48) | DPP4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | GENENTECH, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | FAP, FIBP, FGFR1 | DPP4 305/4885DPP8 220/4885DPP9 145/4885 |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | FAP, FIBP, FGFR1 | DPP4 305/4885DPP8 220/4885DPP9 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.